{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000115","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.709326+00:00","generated_at":"2026-05-17T02:44:53.485748+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose","bullets":["DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.","600 mg QD dose selected via Phase 1b randomized cohort; aligned with FDA, MHRA, and EMA for accelerated approval pathway.","Confirmatory Phase 3 trial planned for H1 2026 with ~400 patients comparing bexobrutideg to pirtobrutinib or chemoimmunotherapy.","NX-1607 Phase 1a data showed disease control rate 49.3% in 82 patients; confirmed partial response in MSS colorectal cancer.","Preclinical data presented claim superior degradation potency and selectivity across BTK mutations; investor webcast held Oct 22."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000115","json":"https://secwatch.observer/filing/0001549595-25-000115.json","markdown":"https://secwatch.observer/filing/0001549595-25-000115.md","text":"https://secwatch.observer/filing/0001549595-25-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000115/0001549595-25-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000115/nrix-20251022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:44:53.485748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}